[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWY8TNNZlS0Y5fiSgTD5-xrh07JM2icRk7MMeZ8UJPYU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":37,"phaseBuckets":82,"rows":89},"University of Vermont",[4,6],"University of Vermont Medical Center",261,false,41,6,54966,11,186,[15,18,21,24,27,30,32,34],{"name":16,"count":17},"Obesity",17,{"name":19,"count":20},"Tobacco Use Disorder",10,{"name":22,"count":23},"Breast Cancer",9,{"name":25,"count":26},"Opioid-Related Disorders",8,{"name":28,"count":29},"Asthma",7,{"name":31,"count":10},"Cancer",{"name":33,"count":10},"Smoking Cessation",{"name":35,"count":36},"Overweight",4,[38,43,48,53,58,63,68,72,77],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06648785","Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies","2026-11","oxaliplatin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05683808","Venous Thromboembolism Prevention in Outpatients With Glioma","2026-12-30","Apixaban",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05603715","Pyridostigmine for the Treatment of Constipation in Parkinson Disease","2026-12-31","Pyridostigmine Bromide",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06972875","Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer","2027-01","Fezolinetant",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04311762","Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer","2029-03-01","cisplatin",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07014462","A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML","2029-06","Dexamethasone plus Venetoclax-based Low-Intensity Therapy",{"nctId":69,"briefTitle":70,"date":71,"intervention":62},"NCT07495098","Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer","2030-07-01",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07477418","PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","2030-12","Gemcitabine Delivered by Transarterial Microperfusion",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07005024","DOAC - Dosing Options in AntiCoagulation Prophylaxis","2035-08","Apixaban 2.5 mg twice daily",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,116,134,152,175,197,221,244,262,286,316,336,373,398,424,448,474,492,510,536,554,582,600,625,650,668,696,714,732,758,785,803,868,905,932,957,986,1004,1030,1048,1066,1090,1117,1135,1156,1180,1204,1227,1252,1277,1302,1320,1345,1372,1390,1417,1441,1466,1493,1511,1534,1559,1585,1612,1636,1660,1684,1710,1728,1750,1773,1798,1825,1859,1884,1910,1928,1952,1980,2005,2029,2053,2078,2103,2121,2146,2164,2182,2200,2226,2253,2271,2289],{"intervention":81,"totalTrials":91,"cells":92},1,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":112,"NA":114},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":91,"soonestReadout":80},[102],{"nctId":78,"briefTitle":79,"status":103,"phases":104,"primaryCompletion":80,"completion":80,"start":105,"enrollment":106,"conditions":107,"interventions":109},"RECRUITING",[86],"2025-10-17",996,[31,108],"VTE (Venous Thromboembolism)",[81,110,111],"Apixaban 5 mg once daily","No anticoagulation",{"trials":113,"activeCount":95},[],{"trials":115,"activeCount":95},[],{"intervention":110,"totalTrials":91,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":130,"NA":132},{"trials":119,"activeCount":95},[],{"trials":121,"activeCount":95},[],{"trials":123,"activeCount":95},[],{"trials":125,"activeCount":91,"soonestReadout":80},[126],{"nctId":78,"briefTitle":79,"status":103,"phases":127,"primaryCompletion":80,"completion":80,"start":105,"enrollment":106,"conditions":128,"interventions":129},[86],[31,108],[81,110,111],{"trials":131,"activeCount":95},[],{"trials":133,"activeCount":95},[],{"intervention":111,"totalTrials":91,"cells":135},{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":148,"NA":150},{"trials":137,"activeCount":95},[],{"trials":139,"activeCount":95},[],{"trials":141,"activeCount":95},[],{"trials":143,"activeCount":91,"soonestReadout":80},[144],{"nctId":78,"briefTitle":79,"status":103,"phases":145,"primaryCompletion":80,"completion":80,"start":105,"enrollment":106,"conditions":146,"interventions":147},[86],[31,108],[81,110,111],{"trials":149,"activeCount":95},[],{"trials":151,"activeCount":95},[],{"intervention":57,"totalTrials":91,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":169,"PHASE4":171,"NA":173},{"trials":155,"activeCount":95},[],{"trials":157,"activeCount":95},[],{"trials":159,"activeCount":91,"soonestReadout":56},[160],{"nctId":54,"briefTitle":55,"status":103,"phases":161,"primaryCompletion":56,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":168},[85],"2027-02","2025-12-18",32,[166,167],"Prostate CA","Androgen Deprivation Therapy",[57],{"trials":170,"activeCount":95},[],{"trials":172,"activeCount":95},[],{"trials":174,"activeCount":95},[],{"intervention":52,"totalTrials":91,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":178,"activeCount":95},[],{"trials":180,"activeCount":95},[],{"trials":182,"activeCount":91,"soonestReadout":51},[183],{"nctId":49,"briefTitle":50,"status":103,"phases":184,"primaryCompletion":51,"completion":51,"start":185,"enrollment":186,"conditions":187,"interventions":190},[85],"2022-08-10",16,[188,189],"Parkinson Disease","Constipation",[52],{"trials":192,"activeCount":95},[],{"trials":194,"activeCount":95},[],{"trials":196,"activeCount":95},[],{"intervention":47,"totalTrials":91,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":215,"PHASE4":217,"NA":219},{"trials":200,"activeCount":95},[],{"trials":202,"activeCount":95},[],{"trials":204,"activeCount":91,"soonestReadout":46},[205],{"nctId":44,"briefTitle":45,"status":103,"phases":206,"primaryCompletion":46,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":214},[85],"2027-06-30","2023-01-16",40,[211,212,213],"Glioblastoma","Astrocytoma","Venous Thromboembolism",[47],{"trials":216,"activeCount":95},[],{"trials":218,"activeCount":95},[],{"trials":220,"activeCount":95},[],{"intervention":42,"totalTrials":91,"cells":222},{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":238,"PHASE4":240,"NA":242},{"trials":224,"activeCount":95},[],{"trials":226,"activeCount":95},[],{"trials":228,"activeCount":91,"soonestReadout":41},[229],{"nctId":39,"briefTitle":40,"status":230,"phases":231,"primaryCompletion":41,"completion":41,"start":232,"enrollment":233,"conditions":234,"interventions":236},"ENROLLING_BY_INVITATION",[85],"2024-10-21",20,[235],"GI Cancers",[42,237],"Fluoropyrimidine",{"trials":239,"activeCount":95},[],{"trials":241,"activeCount":95},[],{"trials":243,"activeCount":95},[],{"intervention":237,"totalTrials":91,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":256,"PHASE4":258,"NA":260},{"trials":247,"activeCount":95},[],{"trials":249,"activeCount":95},[],{"trials":251,"activeCount":91,"soonestReadout":41},[252],{"nctId":39,"briefTitle":40,"status":230,"phases":253,"primaryCompletion":41,"completion":41,"start":232,"enrollment":233,"conditions":254,"interventions":255},[85],[235],[42,237],{"trials":257,"activeCount":95},[],{"trials":259,"activeCount":95},[],{"trials":261,"activeCount":95},[],{"intervention":76,"totalTrials":91,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":265,"activeCount":95},[],{"trials":267,"activeCount":95},[],{"trials":269,"activeCount":91,"soonestReadout":75},[270],{"nctId":73,"briefTitle":74,"status":271,"phases":272,"primaryCompletion":75,"completion":273,"start":274,"enrollment":20,"conditions":275,"interventions":279},"NOT_YET_RECRUITING",[84,85],"2031-12","2026-12",[276,277,278],"Pancreatic Ductal Adenocarcinoma (PDAC)","Borderline Resectable Pancreatic Cancer","Pancreatic Neoplasms",[76],{"trials":281,"activeCount":95},[],{"trials":283,"activeCount":95},[],{"trials":285,"activeCount":95},[],{"intervention":62,"totalTrials":287,"cells":288},2,{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":290,"activeCount":95},[],{"trials":292,"activeCount":287,"soonestReadout":61},[293,300],{"nctId":59,"briefTitle":60,"status":294,"phases":295,"primaryCompletion":61,"completion":61,"start":296,"enrollment":186,"conditions":297,"interventions":299},"ACTIVE_NOT_RECRUITING",[84],"2020-02-01",[298],"Lung Cancer Metastatic",[62],{"nctId":69,"briefTitle":70,"status":271,"phases":301,"primaryCompletion":71,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},[84],"2031-06-30","2026-07-01",12,[298,306],"Lung Cancer (NSCLC)",[62],{"trials":309,"activeCount":95},[],{"trials":311,"activeCount":95},[],{"trials":313,"activeCount":95},[],{"trials":315,"activeCount":95},[],{"intervention":67,"totalTrials":91,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":319,"activeCount":95},[],{"trials":321,"activeCount":91,"soonestReadout":66},[322],{"nctId":64,"briefTitle":65,"status":230,"phases":323,"primaryCompletion":66,"completion":66,"start":324,"enrollment":233,"conditions":325,"interventions":327},[84],"2025-09-01",[326],"AML - Acute Myeloid Leukemia",[67],{"trials":329,"activeCount":95},[],{"trials":331,"activeCount":95},[],{"trials":333,"activeCount":95},[],{"trials":335,"activeCount":95},[],{"intervention":337,"totalTrials":287,"cells":338},"Pioglitazone",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":356,"PHASE4":358,"NA":371},{"trials":340,"activeCount":95},[],{"trials":342,"activeCount":95},[],{"trials":344,"activeCount":95},[345],{"nctId":346,"briefTitle":347,"status":348,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":355},"NCT00787644","Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)","TERMINATED",[85],"2013-06","2013-12","2009-01",28,[28,16],[337],{"trials":357,"activeCount":95},[],{"trials":359,"activeCount":95},[360],{"nctId":361,"briefTitle":362,"status":363,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT00656864","Pioglitazone Incretin Study","COMPLETED",[87],"2010-11","2008-05",24,[369],"Diabetes Mellitus, Type 2",[337],{"trials":372,"activeCount":95},[],{"intervention":374,"totalTrials":91,"cells":375},"Midazolam",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":396},{"trials":377,"activeCount":95},[],{"trials":379,"activeCount":95},[],{"trials":381,"activeCount":95},[],{"trials":383,"activeCount":95},[],{"trials":385,"activeCount":95},[386],{"nctId":387,"briefTitle":388,"status":363,"phases":389,"primaryCompletion":390,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":395},"NCT01375634","Nasogastric Tube Insertion Using Midazolam in the Emergency Department",[87],"2013-04","2011-05",49,[394],"Intubation; Difficult",[374],{"trials":397,"activeCount":95},[],{"intervention":399,"totalTrials":91,"cells":400},"Intravenous Lidocaine",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":422},{"trials":402,"activeCount":95},[],{"trials":404,"activeCount":95},[],{"trials":406,"activeCount":95},[],{"trials":408,"activeCount":95},[],{"trials":410,"activeCount":95},[411],{"nctId":412,"briefTitle":413,"status":348,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":421},"NCT03624985","The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery",[87],"2019-10-14","2018-06-04",61,[419,420],"Pain, Postoperative","Opioid Use",[399],{"trials":423,"activeCount":95},[],{"intervention":425,"totalTrials":91,"cells":426},"nicotine patch",{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":446},{"trials":428,"activeCount":95},[],{"trials":430,"activeCount":95},[],{"trials":432,"activeCount":95},[],{"trials":434,"activeCount":95},[],{"trials":436,"activeCount":95},[437],{"nctId":438,"briefTitle":439,"status":440,"phases":441,"primaryCompletion":351,"completion":351,"start":442,"enrollment":233,"conditions":443,"interventions":445},"NCT01216904","Nicotine Treatment of Impulsivity in Parkinson's Disease","UNKNOWN",[87],"2010-10",[444],"Parkinson's Disease",[425],{"trials":447,"activeCount":95},[],{"intervention":449,"totalTrials":91,"cells":450},"Peginterferon alfa-2a",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":472},{"trials":452,"activeCount":95},[],{"trials":454,"activeCount":95},[],{"trials":456,"activeCount":95},[],{"trials":458,"activeCount":95},[],{"trials":460,"activeCount":95},[461],{"nctId":462,"briefTitle":463,"status":464,"phases":465,"primaryCompletion":466,"completion":466,"start":466,"enrollment":95,"conditions":467,"interventions":469},"NCT01415141","Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism","WITHDRAWN",[87],"2011-07",[468],"Hepatitis C",[449,470,471],"Ribavirin","telaprevir",{"trials":473,"activeCount":95},[],{"intervention":470,"totalTrials":91,"cells":475},{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":490},{"trials":477,"activeCount":95},[],{"trials":479,"activeCount":95},[],{"trials":481,"activeCount":95},[],{"trials":483,"activeCount":95},[],{"trials":485,"activeCount":95},[486],{"nctId":462,"briefTitle":463,"status":464,"phases":487,"primaryCompletion":466,"completion":466,"start":466,"enrollment":95,"conditions":488,"interventions":489},[87],[468],[449,470,471],{"trials":491,"activeCount":95},[],{"intervention":471,"totalTrials":91,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":502,"NA":508},{"trials":495,"activeCount":95},[],{"trials":497,"activeCount":95},[],{"trials":499,"activeCount":95},[],{"trials":501,"activeCount":95},[],{"trials":503,"activeCount":95},[504],{"nctId":462,"briefTitle":463,"status":464,"phases":505,"primaryCompletion":466,"completion":466,"start":466,"enrollment":95,"conditions":506,"interventions":507},[87],[468],[449,470,471],{"trials":509,"activeCount":95},[],{"intervention":511,"totalTrials":91,"cells":512},"Remifentanil",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":534},{"trials":514,"activeCount":95},[],{"trials":516,"activeCount":95},[],{"trials":518,"activeCount":95},[],{"trials":520,"activeCount":95},[],{"trials":522,"activeCount":95},[523],{"nctId":524,"briefTitle":525,"status":440,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT03783676","Does Precise Delivery of Remifentanil Decrease Coughing at Emergence From Anesthesia",[87],"2019-06","2019-02-15",60,[531],"Cough",[511,533],"Normal saline",{"trials":535,"activeCount":95},[],{"intervention":533,"totalTrials":91,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":552},{"trials":539,"activeCount":95},[],{"trials":541,"activeCount":95},[],{"trials":543,"activeCount":95},[],{"trials":545,"activeCount":95},[],{"trials":547,"activeCount":95},[548],{"nctId":524,"briefTitle":525,"status":440,"phases":549,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":550,"interventions":551},[87],[531],[511,533],{"trials":553,"activeCount":95},[],{"intervention":555,"totalTrials":91,"cells":556},"Rotarix, dose 1",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":580},{"trials":558,"activeCount":95},[],{"trials":560,"activeCount":95},[],{"trials":562,"activeCount":95},[],{"trials":564,"activeCount":95},[],{"trials":566,"activeCount":95},[567],{"nctId":568,"briefTitle":569,"status":363,"phases":570,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":578},"NCT02992197","The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity",[87],"2018-06-07","2017-06-12",220,[575,576,577],"Rotavirus Infection","Vaccine Response Impaired","Vaccine Virus Shedding",[555,579],"Rotarix, dose 2",{"trials":581,"activeCount":95},[],{"intervention":579,"totalTrials":91,"cells":583},{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":598},{"trials":585,"activeCount":95},[],{"trials":587,"activeCount":95},[],{"trials":589,"activeCount":95},[],{"trials":591,"activeCount":95},[],{"trials":593,"activeCount":95},[594],{"nctId":568,"briefTitle":569,"status":363,"phases":595,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":596,"interventions":597},[87],[575,576,577],[555,579],{"trials":599,"activeCount":95},[],{"intervention":601,"totalTrials":91,"cells":602},"Sitagliptin",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":623},{"trials":604,"activeCount":95},[],{"trials":606,"activeCount":95},[],{"trials":608,"activeCount":95},[],{"trials":610,"activeCount":95},[],{"trials":612,"activeCount":95},[613],{"nctId":614,"briefTitle":615,"status":440,"phases":616,"primaryCompletion":617,"completion":618,"start":619,"enrollment":233,"conditions":620,"interventions":622},"NCT00732121","Bone Turnover in Type 2 Diabetes Patients",[87],"2010-06","2010-08","2008-08",[621],"Type 2 Diabetes",[601],{"trials":624,"activeCount":95},[],{"intervention":626,"totalTrials":91,"cells":627},"nicotine patch, experimental use",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":634,"PHASE4":636,"NA":648},{"trials":629,"activeCount":95},[],{"trials":631,"activeCount":95},[],{"trials":633,"activeCount":95},[],{"trials":635,"activeCount":95},[],{"trials":637,"activeCount":95},[638],{"nctId":639,"briefTitle":640,"status":363,"phases":641,"primaryCompletion":642,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":646},"NCT01807871","Treatment of Smoking Lapses and Relapses",[87],"2016-02","2013-03",701,[33],[626,647],"nicotine patch, labeled use",{"trials":649,"activeCount":95},[],{"intervention":647,"totalTrials":91,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":660,"NA":666},{"trials":653,"activeCount":95},[],{"trials":655,"activeCount":95},[],{"trials":657,"activeCount":95},[],{"trials":659,"activeCount":95},[],{"trials":661,"activeCount":95},[662],{"nctId":639,"briefTitle":640,"status":363,"phases":663,"primaryCompletion":642,"completion":642,"start":643,"enrollment":644,"conditions":664,"interventions":665},[87],[33],[626,647],{"trials":667,"activeCount":95},[],{"intervention":669,"totalTrials":91,"cells":670},"Clonidine",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":694},{"trials":672,"activeCount":95},[],{"trials":674,"activeCount":95},[],{"trials":676,"activeCount":95},[],{"trials":678,"activeCount":95},[],{"trials":680,"activeCount":95},[681],{"nctId":682,"briefTitle":683,"status":440,"phases":684,"primaryCompletion":685,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":690},"NCT03057015","Addition of Clonidine to Ropivacaine in Adductor Canal Block",[87],"2019-02-28","2017-05-22",80,[689],"Postoperative Pain",[669,691,692,693],"Ropivacaine","Dexamethasone","Epinephrine",{"trials":695,"activeCount":95},[],{"intervention":691,"totalTrials":91,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":712},{"trials":699,"activeCount":95},[],{"trials":701,"activeCount":95},[],{"trials":703,"activeCount":95},[],{"trials":705,"activeCount":95},[],{"trials":707,"activeCount":95},[708],{"nctId":682,"briefTitle":683,"status":440,"phases":709,"primaryCompletion":685,"completion":685,"start":686,"enrollment":687,"conditions":710,"interventions":711},[87],[689],[669,691,692,693],{"trials":713,"activeCount":95},[],{"intervention":693,"totalTrials":91,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":730},{"trials":717,"activeCount":95},[],{"trials":719,"activeCount":95},[],{"trials":721,"activeCount":95},[],{"trials":723,"activeCount":95},[],{"trials":725,"activeCount":95},[726],{"nctId":682,"briefTitle":683,"status":440,"phases":727,"primaryCompletion":685,"completion":685,"start":686,"enrollment":687,"conditions":728,"interventions":729},[87],[689],[669,691,692,693],{"trials":731,"activeCount":95},[],{"intervention":733,"totalTrials":91,"cells":734},"Mg Cl",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":754,"NA":756},{"trials":736,"activeCount":95},[],{"trials":738,"activeCount":95},[],{"trials":740,"activeCount":95},[],{"trials":742,"activeCount":95},[743],{"nctId":744,"briefTitle":745,"status":363,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT02466087","Role of Magnesium Supplementation in the Treatment of Depression",[85,86],"2016-05","2016-12","2015-05",126,[752],"Depression",[733],{"trials":755,"activeCount":95},[],{"trials":757,"activeCount":95},[],{"intervention":759,"totalTrials":91,"cells":760},"IPV",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":781,"NA":783},{"trials":762,"activeCount":95},[],{"trials":764,"activeCount":95},[],{"trials":766,"activeCount":95},[],{"trials":768,"activeCount":95},[769],{"nctId":770,"briefTitle":771,"status":363,"phases":772,"primaryCompletion":773,"completion":774,"start":391,"enrollment":775,"conditions":776,"interventions":779},"NCT01375647","Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh",[86],"2014-10","2014-11",700,[777,577,778],"Rotavirus Diarrhea","Tropical Enteropathy",[759,780],"Rotarix",{"trials":782,"activeCount":95},[],{"trials":784,"activeCount":95},[],{"intervention":780,"totalTrials":91,"cells":786},{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":793,"PHASE4":799,"NA":801},{"trials":788,"activeCount":95},[],{"trials":790,"activeCount":95},[],{"trials":792,"activeCount":95},[],{"trials":794,"activeCount":95},[795],{"nctId":770,"briefTitle":771,"status":363,"phases":796,"primaryCompletion":773,"completion":774,"start":391,"enrollment":775,"conditions":797,"interventions":798},[86],[777,577,778],[759,780],{"trials":800,"activeCount":95},[],{"trials":802,"activeCount":95},[],{"intervention":804,"totalTrials":29,"cells":805},"Buprenorphine",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":818,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":807,"activeCount":95},[],{"trials":809,"activeCount":95},[810],{"nctId":811,"briefTitle":812,"status":363,"phases":813,"completion":814,"start":815,"enrollment":95,"conditions":816,"interventions":817},"NCT00000219","Buprenorphine Dose Alteration Study - 1",[84],"2001-07","1991-12",[25],[804],{"trials":819,"activeCount":95},[820,827,834,840,848,855],{"nctId":821,"briefTitle":822,"status":363,"phases":823,"start":824,"enrollment":95,"conditions":825,"interventions":826},"NCT00000230","Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12",[85],"1995-01",[25],[804],{"nctId":828,"briefTitle":829,"status":363,"phases":830,"start":831,"enrollment":95,"conditions":832,"interventions":833},"NCT00000232","Alternate Day Buprenorphine Administration, Phase IX - 14",[85],"1992-03",[25],[804],{"nctId":835,"briefTitle":836,"status":363,"phases":837,"enrollment":95,"conditions":838,"interventions":839},"NCT00000234","Alternate Day Buprenorphine Administration, Phase XI - 16",[85],[25],[804],{"nctId":841,"briefTitle":842,"status":363,"phases":843,"start":844,"enrollment":95,"conditions":845,"interventions":847},"NCT00000240","Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22",[85],"1999-04",[846,25],"Cocaine-Related Disorders",[804],{"nctId":849,"briefTitle":850,"status":363,"phases":851,"start":852,"enrollment":95,"conditions":853,"interventions":854},"NCT00000229","Buprenorphine Detox With Two Types of Treatment. BBD II - 11",[85],"1995-10",[25],[804],{"nctId":856,"briefTitle":857,"status":363,"phases":858,"start":859,"enrollment":95,"conditions":860,"interventions":861},"NCT00000227","Alternate-Day Buprenorphine Administration. Phase VIII - 9",[85],"1994-08",[25],[804],{"trials":863,"activeCount":95},[],{"trials":865,"activeCount":95},[],{"trials":867,"activeCount":95},[],{"intervention":869,"totalTrials":287,"cells":870},"Nicotine",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":899,"PHASE4":901,"NA":903},{"trials":872,"activeCount":95},[],{"trials":874,"activeCount":95},[],{"trials":876,"activeCount":95},[877,890],{"nctId":878,"briefTitle":879,"status":363,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":889},"NCT04709471","E-cigarette Nicotine Study",[85],"2022-04-26","2022-06-01","2021-01-20",77,[886,887,888],"Nicotine Dependence","Electronic Cigarette Use","Cigarette Smoking",[869],{"nctId":891,"briefTitle":892,"status":363,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":898},"NCT04696380","Do Flavors Increase the Addiction Potential of Nicotine?",[85],"2021-08-31","2021-03-01",19,[886],[869],{"trials":900,"activeCount":95},[],{"trials":902,"activeCount":95},[],{"trials":904,"activeCount":95},[],{"intervention":906,"totalTrials":91,"cells":907},"Rosuvastatin",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":926,"PHASE4":928,"NA":930},{"trials":909,"activeCount":95},[],{"trials":911,"activeCount":95},[],{"trials":913,"activeCount":95},[914],{"nctId":915,"briefTitle":916,"status":363,"phases":917,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":925},"NCT01524653","Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)",[85],"2016-07-01","2016-09-01","2012-03",38,[213,923,924],"Deep Vein Thrombosis","Neoplasms",[906],{"trials":927,"activeCount":95},[],{"trials":929,"activeCount":95},[],{"trials":931,"activeCount":95},[],{"intervention":933,"totalTrials":91,"cells":934},"tinzaparin sodium",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":936,"activeCount":95},[],{"trials":938,"activeCount":95},[],{"trials":940,"activeCount":95},[941],{"nctId":942,"briefTitle":943,"status":440,"phases":944,"primaryCompletion":945,"start":946,"enrollment":947,"conditions":948,"interventions":950},"NCT00293501","Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery",[84,85],"2007-02","2005-12",35,[949],"Kidney Cancer",[933],{"trials":952,"activeCount":95},[],{"trials":954,"activeCount":95},[],{"trials":956,"activeCount":95},[],{"intervention":958,"totalTrials":91,"cells":959},"Nicotine replacement therapy patch",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":961,"activeCount":95},[],{"trials":963,"activeCount":95},[],{"trials":965,"activeCount":95},[966],{"nctId":967,"briefTitle":968,"status":363,"phases":969,"primaryCompletion":970,"completion":971,"start":972,"enrollment":973,"conditions":974,"interventions":978},"NCT04946825","Quit Smoking Study for People Who Use E-Cigarettes",[85],"2023-08-02","2023-10-25","2021-06-27",396,[975,976,977],"Nicotine Addiction","E-Cig Use","Quitting Smoking",[958,979],"Nicotine replacement therapy lozenge",{"trials":981,"activeCount":95},[],{"trials":983,"activeCount":95},[],{"trials":985,"activeCount":95},[],{"intervention":979,"totalTrials":91,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":989,"activeCount":95},[],{"trials":991,"activeCount":95},[],{"trials":993,"activeCount":95},[994],{"nctId":967,"briefTitle":968,"status":363,"phases":995,"primaryCompletion":970,"completion":971,"start":972,"enrollment":973,"conditions":996,"interventions":997},[85],[975,976,977],[958,979],{"trials":999,"activeCount":95},[],{"trials":1001,"activeCount":95},[],{"trials":1003,"activeCount":95},[],{"intervention":1005,"totalTrials":91,"cells":1006},"Gemcitabine",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1008,"activeCount":95},[],{"trials":1010,"activeCount":95},[],{"trials":1012,"activeCount":95},[1013],{"nctId":1014,"briefTitle":1015,"status":363,"phases":1016,"primaryCompletion":1017,"completion":1017,"start":1018,"enrollment":10,"conditions":1019,"interventions":1021},"NCT01719302","Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma",[84,85],"2015-04","2012-10",[1020],"Stage III Adult Soft Tissue Sarcoma",[1005,1022,1023],"Docetaxel","Pazopanib",{"trials":1025,"activeCount":95},[],{"trials":1027,"activeCount":95},[],{"trials":1029,"activeCount":95},[],{"intervention":1022,"totalTrials":91,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1033,"activeCount":95},[],{"trials":1035,"activeCount":95},[],{"trials":1037,"activeCount":95},[1038],{"nctId":1014,"briefTitle":1015,"status":363,"phases":1039,"primaryCompletion":1017,"completion":1017,"start":1018,"enrollment":10,"conditions":1040,"interventions":1041},[84,85],[1020],[1005,1022,1023],{"trials":1043,"activeCount":95},[],{"trials":1045,"activeCount":95},[],{"trials":1047,"activeCount":95},[],{"intervention":1023,"totalTrials":91,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":95},[],{"trials":1053,"activeCount":95},[],{"trials":1055,"activeCount":95},[1056],{"nctId":1014,"briefTitle":1015,"status":363,"phases":1057,"primaryCompletion":1017,"completion":1017,"start":1018,"enrollment":10,"conditions":1058,"interventions":1059},[84,85],[1020],[1005,1022,1023],{"trials":1061,"activeCount":95},[],{"trials":1063,"activeCount":95},[],{"trials":1065,"activeCount":95},[],{"intervention":1067,"totalTrials":91,"cells":1068},"Rituximab",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1070,"activeCount":95},[],{"trials":1072,"activeCount":95},[],{"trials":1074,"activeCount":95},[1075],{"nctId":1076,"briefTitle":1077,"status":363,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":20,"conditions":1081,"interventions":1083},"NCT00619671","A Pilot Trial of Rituxan in Refractory Myasthenia Gravis",[84,85],"2009-03","2004-04",[1082],"Refractory Myasthenia Gravis",[1067],{"trials":1085,"activeCount":95},[],{"trials":1087,"activeCount":95},[],{"trials":1089,"activeCount":95},[],{"intervention":1091,"totalTrials":91,"cells":1092},"aprepitant",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1094,"activeCount":95},[],{"trials":1096,"activeCount":95},[],{"trials":1098,"activeCount":95},[1099],{"nctId":1100,"briefTitle":1101,"status":363,"phases":1102,"primaryCompletion":918,"completion":1103,"start":1104,"enrollment":1105,"conditions":1106,"interventions":1109},"NCT00970905","Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy",[85],"2016-08-01","2009-10",52,[1107,1108],"Nausea","Vomiting",[1091,1110],"Ondansetron",{"trials":1112,"activeCount":95},[],{"trials":1114,"activeCount":95},[],{"trials":1116,"activeCount":95},[],{"intervention":1110,"totalTrials":91,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1120,"activeCount":95},[],{"trials":1122,"activeCount":95},[],{"trials":1124,"activeCount":95},[1125],{"nctId":1100,"briefTitle":1101,"status":363,"phases":1126,"primaryCompletion":918,"completion":1103,"start":1104,"enrollment":1105,"conditions":1127,"interventions":1128},[85],[1107,1108],[1091,1110],{"trials":1130,"activeCount":95},[],{"trials":1132,"activeCount":95},[],{"trials":1134,"activeCount":95},[],{"intervention":1136,"totalTrials":91,"cells":1137},"Methylnaltrexone bromide",{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1139,"activeCount":95},[],{"trials":1141,"activeCount":95},[],{"trials":1143,"activeCount":95},[1144],{"nctId":1145,"briefTitle":1146,"status":363,"phases":1147,"primaryCompletion":351,"completion":351,"start":1104,"enrollment":304,"conditions":1148,"interventions":1149},"NCT01004393","Methylnaltrexone for Opioid-induced Constipation in Cancer Patients",[85],[924,189,25],[1136],{"trials":1151,"activeCount":95},[],{"trials":1153,"activeCount":95},[],{"trials":1155,"activeCount":95},[],{"intervention":1157,"totalTrials":91,"cells":1158},"Atorvastatin",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1160,"activeCount":95},[],{"trials":1162,"activeCount":95},[],{"trials":1164,"activeCount":95},[1165],{"nctId":1166,"briefTitle":1167,"status":440,"phases":1168,"primaryCompletion":1169,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1173},"NCT00914017","Statins and Breast Cancer Biomarkers",[85],"2010-12","2005-01",100,[22],[1157],{"trials":1175,"activeCount":95},[],{"trials":1177,"activeCount":95},[],{"trials":1179,"activeCount":95},[],{"intervention":1181,"totalTrials":91,"cells":1182},"Buprenorphine\u002Fnaloxone sublingual",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1184,"activeCount":95},[],{"trials":1186,"activeCount":95},[],{"trials":1188,"activeCount":95},[1189],{"nctId":1190,"briefTitle":1191,"status":440,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1171,"conditions":1195,"interventions":1197},"NCT03420313","Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation",[85],"2021-07","2018-03-01",[1196],"Opioid-use Disorder",[1181],{"trials":1199,"activeCount":95},[],{"trials":1201,"activeCount":95},[],{"trials":1203,"activeCount":95},[],{"intervention":1205,"totalTrials":91,"cells":1206},"Loratadine",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1208,"activeCount":95},[],{"trials":1210,"activeCount":95},[],{"trials":1212,"activeCount":95},[1213],{"nctId":1214,"briefTitle":1215,"status":440,"phases":1216,"primaryCompletion":350,"completion":350,"start":391,"enrollment":1217,"conditions":1218,"interventions":1220},"NCT01311336","Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain",[85],55,[1219],"Pegfilgrastim-induced Back and Leg Pain",[1205],{"trials":1222,"activeCount":95},[],{"trials":1224,"activeCount":95},[],{"trials":1226,"activeCount":95},[],{"intervention":1228,"totalTrials":91,"cells":1229},"buprenorphine taper followed by naltrexone maintenance",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1231,"activeCount":95},[],{"trials":1233,"activeCount":95},[],{"trials":1235,"activeCount":95},[1236],{"nctId":1237,"briefTitle":1238,"status":363,"phases":1239,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT00719095","Effective Treatment for Prescription Opioid Abuse",[85],"2010-03","2006-04",105,[1244],"Prescription Opioid Dependence",[1228],{"trials":1247,"activeCount":95},[],{"trials":1249,"activeCount":95},[],{"trials":1251,"activeCount":95},[],{"intervention":1253,"totalTrials":91,"cells":1254},"Interim Buprenorphine Treatment",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1256,"activeCount":95},[],{"trials":1258,"activeCount":95},[],{"trials":1260,"activeCount":95},[1261],{"nctId":1262,"briefTitle":1263,"status":363,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1270},"NCT02360007","Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access",[84,85],"2016-06","2015-01",70,[1269],"Opioid-related Disorders",[1253],{"trials":1272,"activeCount":95},[],{"trials":1274,"activeCount":95},[],{"trials":1276,"activeCount":95},[],{"intervention":1278,"totalTrials":91,"cells":1279},"Pre-Quit Nicotine Lozenges",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1281,"activeCount":95},[],{"trials":1283,"activeCount":95},[],{"trials":1285,"activeCount":95},[1286],{"nctId":1287,"briefTitle":1288,"status":363,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1294},"NCT00297492","Gradual vs. Abrupt Cessation Treatment for Smoking",[85],"2008-02","2006-01",750,[33],[1278,1295],"Post-Quit Nicotine Lozenges",{"trials":1297,"activeCount":95},[],{"trials":1299,"activeCount":95},[],{"trials":1301,"activeCount":95},[],{"intervention":1295,"totalTrials":91,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1305,"activeCount":95},[],{"trials":1307,"activeCount":95},[],{"trials":1309,"activeCount":95},[1310],{"nctId":1287,"briefTitle":1288,"status":363,"phases":1311,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1312,"interventions":1313},[85],[33],[1278,1295],{"trials":1315,"activeCount":95},[],{"trials":1317,"activeCount":95},[],{"trials":1319,"activeCount":95},[],{"intervention":1321,"totalTrials":91,"cells":1322},"Pulmozyme",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1324,"activeCount":95},[],{"trials":1326,"activeCount":95},[],{"trials":1328,"activeCount":95},[1329],{"nctId":1330,"briefTitle":1331,"status":363,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":186,"conditions":1335,"interventions":1338},"NCT00416182","Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis",[85],"2012-06","2006-12",[1336,1337],"Sinusitis","Cystic Fibrosis",[1321],{"trials":1340,"activeCount":95},[],{"trials":1342,"activeCount":95},[],{"trials":1344,"activeCount":95},[],{"intervention":1346,"totalTrials":91,"cells":1347},"Docetaxel\u002Fcisplatin",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1349,"activeCount":95},[],{"trials":1351,"activeCount":95},[],{"trials":1353,"activeCount":95},[1354],{"nctId":1355,"briefTitle":1356,"status":440,"phases":1357,"primaryCompletion":1358,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1364},"NCT00982436","Neoadjuvant Cisplatin\u002FDocetaxel (CDDP\u002FTXT) and Chemoradiation for Head and Neck Cancer",[84,85],"2012-09","2012-12","2009-09",37,[1363],"Head and Neck Neoplasms",[1346,1365],"Carboplatin",{"trials":1367,"activeCount":95},[],{"trials":1369,"activeCount":95},[],{"trials":1371,"activeCount":95},[],{"intervention":1365,"totalTrials":91,"cells":1373},{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1375,"activeCount":95},[],{"trials":1377,"activeCount":95},[],{"trials":1379,"activeCount":95},[1380],{"nctId":1355,"briefTitle":1356,"status":440,"phases":1381,"primaryCompletion":1358,"completion":1359,"start":1360,"enrollment":1361,"conditions":1382,"interventions":1383},[84,85],[1363],[1346,1365],{"trials":1385,"activeCount":95},[],{"trials":1387,"activeCount":95},[],{"trials":1389,"activeCount":95},[],{"intervention":1391,"totalTrials":91,"cells":1392},"Testosterone propionate",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1394,"activeCount":95},[],{"trials":1396,"activeCount":95},[],{"trials":1398,"activeCount":95},[1399],{"nctId":1400,"briefTitle":1401,"status":1402,"phases":1403,"primaryCompletion":1169,"completion":1404,"start":1334,"enrollment":1405,"conditions":1406,"interventions":1410},"NCT01122342","Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.","SUSPENDED",[84,85],"2011-01",30,[1407,1408,1409],"Vaginitis","Dyspareunia","Breast Neoplasms",[1391],{"trials":1412,"activeCount":95},[],{"trials":1414,"activeCount":95},[],{"trials":1416,"activeCount":95},[],{"intervention":1418,"totalTrials":91,"cells":1419},"Varenicline",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1421,"activeCount":95},[],{"trials":1423,"activeCount":95},[],{"trials":1425,"activeCount":95},[1426],{"nctId":1427,"briefTitle":1428,"status":363,"phases":1429,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":573,"conditions":1432,"interventions":1434},"NCT00595868","Efficacy of Varenicline in Ambivalent Smokers",[85],"2010-01","2008-03",[19,1433,886],"Tobacco Use Cessation",[1418],{"trials":1436,"activeCount":95},[],{"trials":1438,"activeCount":95},[],{"trials":1440,"activeCount":95},[],{"intervention":1442,"totalTrials":91,"cells":1443},"dolastatin 10",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1460,"PHASE4":1462,"NA":1464},{"trials":1445,"activeCount":95},[],{"trials":1447,"activeCount":95},[],{"trials":1449,"activeCount":95},[1450],{"nctId":1451,"briefTitle":1452,"status":363,"phases":1453,"completion":1454,"start":1455,"conditions":1456,"interventions":1459},"NCT00005579","Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia",[85],"2003-02","1998-06",[1457,1458],"Leukemia","Lymphoma",[1442],{"trials":1461,"activeCount":95},[],{"trials":1463,"activeCount":95},[],{"trials":1465,"activeCount":95},[],{"intervention":1467,"totalTrials":91,"cells":1468},"dmLT",{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1485,"PHASE3":1487,"PHASE4":1489,"NA":1491},{"trials":1470,"activeCount":95},[],{"trials":1472,"activeCount":95},[1473],{"nctId":1474,"briefTitle":1475,"status":363,"phases":1476,"primaryCompletion":1477,"completion":1478,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1483},"NCT03922061","Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant",[84],"2019-07-18","2020-06-04","2019-03-19",29,[1482],"Polio",[1467,1484],"fIPV",{"trials":1486,"activeCount":95},[],{"trials":1488,"activeCount":95},[],{"trials":1490,"activeCount":95},[],{"trials":1492,"activeCount":95},[],{"intervention":1484,"totalTrials":91,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1503,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1496,"activeCount":95},[],{"trials":1498,"activeCount":95},[1499],{"nctId":1474,"briefTitle":1475,"status":363,"phases":1500,"primaryCompletion":1477,"completion":1478,"start":1479,"enrollment":1480,"conditions":1501,"interventions":1502},[84],[1482],[1467,1484],{"trials":1504,"activeCount":95},[],{"trials":1506,"activeCount":95},[],{"trials":1508,"activeCount":95},[],{"trials":1510,"activeCount":95},[],{"intervention":1512,"totalTrials":91,"cells":1513},"Tauroursodeoxycholic Acid",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1515,"activeCount":95},[],{"trials":1517,"activeCount":95},[1518],{"nctId":1519,"briefTitle":1520,"status":348,"phases":1521,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":12,"conditions":1524,"interventions":1525},"NCT03878654","Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma",[84],"2019-09-11","2019-01-10",[28],[1512],{"trials":1527,"activeCount":95},[],{"trials":1529,"activeCount":95},[],{"trials":1531,"activeCount":95},[],{"trials":1533,"activeCount":95},[],{"intervention":1535,"totalTrials":91,"cells":1536},"Nifurtimox",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1557},{"trials":1538,"activeCount":95},[],{"trials":1540,"activeCount":95},[1541],{"nctId":1542,"briefTitle":1543,"status":363,"phases":1544,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":233,"conditions":1548,"interventions":1550},"NCT00486564","Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma",[84],"2007-11","2009-06","2006-11",[1549],"Neuroblastoma",[1535],{"trials":1552,"activeCount":95},[],{"trials":1554,"activeCount":95},[],{"trials":1556,"activeCount":95},[],{"trials":1558,"activeCount":95},[],{"intervention":1560,"totalTrials":91,"cells":1561},"Nicotine patch, oral mecamylamine, placebo",{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1577,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1563,"activeCount":95},[],{"trials":1565,"activeCount":95},[1566],{"nctId":1567,"briefTitle":1568,"status":363,"phases":1569,"primaryCompletion":1570,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1576},"NCT03408574","The Nicotinic Cholinergic System and Cognitive Aging",[84],"2021-12-01","2022-01-31","2016-10-01",104,[1575],"Healthy Aging",[1560],{"trials":1578,"activeCount":95},[],{"trials":1580,"activeCount":95},[],{"trials":1582,"activeCount":95},[],{"trials":1584,"activeCount":95},[],{"intervention":1586,"totalTrials":91,"cells":1587},"As needed pharmacological rate control with beta-blocker",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1604,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1589,"activeCount":95},[],{"trials":1591,"activeCount":95},[1592],{"nctId":1593,"briefTitle":1594,"status":440,"phases":1595,"primaryCompletion":1596,"completion":1597,"start":1598,"enrollment":233,"conditions":1599,"interventions":1603},"NCT05745337","Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor",[84],"2023-12-31","2025-12-31","2023-02-06",[1600,1601,1602],"Atrial Fibrillation","Diastolic Dysfunction","HFpEF - Heart Failure With Preserved Ejection Fraction",[1586],{"trials":1605,"activeCount":95},[],{"trials":1607,"activeCount":95},[],{"trials":1609,"activeCount":95},[],{"trials":1611,"activeCount":95},[],{"intervention":1613,"totalTrials":91,"cells":1614},"cis-diamminedichloroplatinum",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1628,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1616,"activeCount":95},[],{"trials":1618,"activeCount":95},[1619],{"nctId":1620,"briefTitle":1621,"status":363,"phases":1622,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":10,"conditions":1625,"interventions":1627},"NCT04809103","Intratumoral Cisplatin for Resectable NSCLC",[84],"2025-10-01","2021-03-08",[1626],"Non-Small Cell Lung Cancer",[1613],{"trials":1629,"activeCount":95},[],{"trials":1631,"activeCount":95},[],{"trials":1633,"activeCount":95},[],{"trials":1635,"activeCount":95},[],{"intervention":1637,"totalTrials":91,"cells":1638},"Campylobacter jejuni strains CG8421 and BH-01-0142",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1652,"PHASE3":1654,"PHASE4":1656,"NA":1658},{"trials":1640,"activeCount":95},[],{"trials":1642,"activeCount":95},[1643],{"nctId":1644,"briefTitle":1645,"status":440,"phases":1646,"primaryCompletion":1647,"completion":1647,"start":945,"enrollment":1648,"conditions":1649,"interventions":1651},"NCT00434798","Campylobacter Jejuni Challenge Model Development: Dose Ranging Study",[84],"2008-10",50,[1650],"Campylobacter Infections",[1637],{"trials":1653,"activeCount":95},[],{"trials":1655,"activeCount":95},[],{"trials":1657,"activeCount":95},[],{"trials":1659,"activeCount":95},[],{"intervention":1661,"totalTrials":91,"cells":1662},"Mitoquinol",{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1676,"PHASE3":1678,"PHASE4":1680,"NA":1682},{"trials":1664,"activeCount":95},[],{"trials":1666,"activeCount":95},[1667],{"nctId":1668,"briefTitle":1669,"status":363,"phases":1670,"primaryCompletion":1671,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1675},"NCT04026711","MitoQ for the Treatment of Metabolic Dysfunction in Asthma",[84],"2024-03-31","2020-01-01",47,[28,16],[1661],{"trials":1677,"activeCount":95},[],{"trials":1679,"activeCount":95},[],{"trials":1681,"activeCount":95},[],{"trials":1683,"activeCount":95},[],{"intervention":1685,"totalTrials":91,"cells":1686},"Intradermal fractional dose inactivated polio vaccine",{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1688,"activeCount":95},[],{"trials":1690,"activeCount":95},[1691],{"nctId":1692,"briefTitle":1693,"status":440,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":896,"conditions":1698,"interventions":1700},"NCT05327426","Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT",[84],"2023-10-10","2024-08-25","2022-04-01",[1699],"Poliomyelitis",[1685,1685,1701],"Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain",{"trials":1703,"activeCount":95},[],{"trials":1705,"activeCount":95},[],{"trials":1707,"activeCount":95},[],{"trials":1709,"activeCount":95},[],{"intervention":1701,"totalTrials":91,"cells":1711},{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1713,"activeCount":95},[],{"trials":1715,"activeCount":95},[1716],{"nctId":1692,"briefTitle":1693,"status":440,"phases":1717,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":896,"conditions":1718,"interventions":1719},[84],[1699],[1685,1685,1701],{"trials":1721,"activeCount":95},[],{"trials":1723,"activeCount":95},[],{"trials":1725,"activeCount":95},[],{"trials":1727,"activeCount":95},[],{"intervention":1729,"totalTrials":91,"cells":1730},"Campylobacter jejuni strain CG8421",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1732,"activeCount":95},[],{"trials":1734,"activeCount":95},[1735],{"nctId":1736,"briefTitle":1737,"status":440,"phases":1738,"primaryCompletion":1169,"completion":1739,"start":1430,"enrollment":186,"conditions":1740,"interventions":1741},"NCT01048112","Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection",[84],"2011-09",[1650],[1729],{"trials":1743,"activeCount":95},[],{"trials":1745,"activeCount":95},[],{"trials":1747,"activeCount":95},[],{"trials":1749,"activeCount":95},[],{"intervention":1751,"totalTrials":91,"cells":1752},"Aspirin",{"EARLY_PHASE1":1753,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1754,"activeCount":95},[1755],{"nctId":1756,"briefTitle":1757,"status":363,"phases":1758,"primaryCompletion":1169,"completion":1359,"start":1759,"enrollment":12,"conditions":1760,"interventions":1762},"NCT00727948","The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy",[83],"2008-07",[22,1761],"Angiogenesis",[1751],{"trials":1764,"activeCount":95},[],{"trials":1766,"activeCount":95},[],{"trials":1768,"activeCount":95},[],{"trials":1770,"activeCount":95},[],{"trials":1772,"activeCount":95},[],{"intervention":1774,"totalTrials":91,"cells":1775},"Fecal Microbiota Transplant",{"EARLY_PHASE1":1776,"PHASE1":1788,"PHASE2":1790,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1777,"activeCount":95},[1778],{"nctId":1779,"briefTitle":1780,"status":440,"phases":1781,"primaryCompletion":1782,"completion":1783,"start":1784,"enrollment":233,"conditions":1785,"interventions":1787},"NCT02390726","Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis",[83],"2017-12","2018-09","2015-12",[1786],"Ulcerative Colitis, Active Moderate",[1774],{"trials":1789,"activeCount":95},[],{"trials":1791,"activeCount":95},[],{"trials":1793,"activeCount":95},[],{"trials":1795,"activeCount":95},[],{"trials":1797,"activeCount":95},[],{"intervention":1799,"totalTrials":91,"cells":1800},"Cholinergic antagonist",{"EARLY_PHASE1":1801,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1821,"NA":1823},{"trials":1802,"activeCount":95},[1803],{"nctId":1804,"briefTitle":1805,"status":363,"phases":1806,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1814},"NCT04129060","Cholinergic Health After Menopause (CHAMP)",[83],"2024-12-16","2020-03-15",120,[1811,1812,1813],"Postmenopausal Symptoms","Aging","Alzheimer Disease",[1799],{"trials":1816,"activeCount":95},[],{"trials":1818,"activeCount":95},[],{"trials":1820,"activeCount":95},[],{"trials":1822,"activeCount":95},[],{"trials":1824,"activeCount":95},[],{"intervention":692,"totalTrials":287,"cells":1826},{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1841},{"trials":1828,"activeCount":95},[],{"trials":1830,"activeCount":95},[],{"trials":1832,"activeCount":95},[],{"trials":1834,"activeCount":95},[],{"trials":1836,"activeCount":95},[1837],{"nctId":682,"briefTitle":683,"status":440,"phases":1838,"primaryCompletion":685,"completion":685,"start":686,"enrollment":687,"conditions":1839,"interventions":1840},[87],[689],[669,691,692,693],{"trials":1842,"activeCount":95},[1843],{"nctId":1844,"briefTitle":1845,"status":363,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1855},"NCT02402543","Pre-Emptive Analgesia in Ano-Rectal Surgery",[88],"2017-05","2014-06",90,[1851,1852,1853,1854],"Hemorrhoids","Fissure in Ano","Rectal Fistula","Anal Condyloma",[1856,1857,1858,692],"Gabapentin","Ketamine","Acetaminophen",{"intervention":1860,"totalTrials":91,"cells":1861},"Cyclophosphamide and Methotrexate and Aspirin",{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1863,"activeCount":95},[],{"trials":1865,"activeCount":95},[],{"trials":1867,"activeCount":95},[],{"trials":1869,"activeCount":95},[],{"trials":1871,"activeCount":95},[],{"trials":1873,"activeCount":95},[1874],{"nctId":1875,"briefTitle":1876,"status":440,"phases":1877,"primaryCompletion":1878,"completion":1879,"start":1880,"enrollment":1881,"conditions":1882,"interventions":1883},"NCT01612247","Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy",[88],"2013-02","2014-02","2011-02",13,[22],[1860],{"intervention":1885,"totalTrials":91,"cells":1886},"Dexamethasone 2.5 mg and Sitagliptin 100 mg",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1888,"activeCount":95},[],{"trials":1890,"activeCount":95},[],{"trials":1892,"activeCount":95},[],{"trials":1894,"activeCount":95},[],{"trials":1896,"activeCount":95},[],{"trials":1898,"activeCount":95},[1899],{"nctId":1900,"briefTitle":1901,"status":363,"phases":1902,"primaryCompletion":1903,"completion":1784,"start":1358,"enrollment":20,"conditions":1904,"interventions":1908},"NCT01488279","Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy",[88],"2014-07",[1905,1906,1907],"Pre-diabetes","Impaired Fasting Glucose","Impaired Glucose Tolerance",[1885,1909],"Dexamethasone 2.5 mg and placebo",{"intervention":1909,"totalTrials":91,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1913,"activeCount":95},[],{"trials":1915,"activeCount":95},[],{"trials":1917,"activeCount":95},[],{"trials":1919,"activeCount":95},[],{"trials":1921,"activeCount":95},[],{"trials":1923,"activeCount":95},[1924],{"nctId":1900,"briefTitle":1901,"status":363,"phases":1925,"primaryCompletion":1903,"completion":1784,"start":1358,"enrollment":20,"conditions":1926,"interventions":1927},[88],[1905,1906,1907],[1885,1909],{"intervention":1929,"totalTrials":91,"cells":1930},"N-acetylcysteine",{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1932,"activeCount":95},[],{"trials":1934,"activeCount":95},[],{"trials":1936,"activeCount":95},[],{"trials":1938,"activeCount":95},[],{"trials":1940,"activeCount":95},[],{"trials":1942,"activeCount":95},[1943],{"nctId":1944,"briefTitle":1945,"status":363,"phases":1946,"primaryCompletion":1947,"completion":1290,"start":1948,"conditions":1949,"interventions":1951},"NCT00498342","The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease",[88],"2008-01","2007-06",[1950],"Chronic Kidney Disease",[1929],{"intervention":1953,"totalTrials":91,"cells":1954},"standard insulin protocol post-op",{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1956,"activeCount":95},[],{"trials":1958,"activeCount":95},[],{"trials":1960,"activeCount":95},[],{"trials":1962,"activeCount":95},[],{"trials":1964,"activeCount":95},[],{"trials":1966,"activeCount":95},[1967],{"nctId":1968,"briefTitle":1969,"status":363,"phases":1970,"primaryCompletion":1265,"completion":1265,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1979},"NCT01916733","A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study",[],"2013-01",89,[1974,1975,1976,1977,1978],"Glycemic Control","Surgical Site Infections","Cardiac Complications","Length of Stay","Cost",[1953],{"intervention":1981,"totalTrials":91,"cells":1982},"Norethindrone",{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":1991,"NA":1993},{"trials":1984,"activeCount":95},[],{"trials":1986,"activeCount":95},[],{"trials":1988,"activeCount":95},[],{"trials":1990,"activeCount":95},[],{"trials":1992,"activeCount":95},[],{"trials":1994,"activeCount":95},[1995],{"nctId":1996,"briefTitle":1997,"status":348,"phases":1998,"completion":1999,"start":2000,"enrollment":233,"conditions":2001,"interventions":2004},"NCT00580424","The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots",[88],"2009-07","2007-12",[2002,2003],"Women's Health","Blood Coagulation Disorders",[1981],{"intervention":2006,"totalTrials":91,"cells":2007},"-aminosalicylic acid",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2009,"activeCount":95},[],{"trials":2011,"activeCount":95},[],{"trials":2013,"activeCount":95},[],{"trials":2015,"activeCount":95},[],{"trials":2017,"activeCount":95},[],{"trials":2019,"activeCount":95},[2020],{"nctId":2021,"briefTitle":2022,"status":363,"phases":2023,"completion":2024,"start":2025,"enrollment":687,"conditions":2026,"interventions":2028},"NCT00004423","Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease",[88],"1998-03","1995-12",[2027],"Crohn's Disease",[2006],{"intervention":2030,"totalTrials":91,"cells":2031},"Definity Contrast",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2033,"activeCount":95},[],{"trials":2035,"activeCount":95},[],{"trials":2037,"activeCount":95},[],{"trials":2039,"activeCount":95},[],{"trials":2041,"activeCount":95},[],{"trials":2043,"activeCount":95},[2044],{"nctId":2045,"briefTitle":2046,"status":464,"phases":2047,"primaryCompletion":2048,"completion":2048,"start":2049,"enrollment":95,"conditions":2050,"interventions":2052},"NCT01526590","Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions",[88],"2013-07","2012-07",[2051],"Pancreatic Tumors",[2030],{"intervention":2054,"totalTrials":91,"cells":2055},"eszopiclone",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2057,"activeCount":95},[],{"trials":2059,"activeCount":95},[],{"trials":2061,"activeCount":95},[],{"trials":2063,"activeCount":95},[],{"trials":2065,"activeCount":95},[],{"trials":2067,"activeCount":95},[2068],{"nctId":2069,"briefTitle":2070,"status":363,"phases":2071,"primaryCompletion":366,"completion":2072,"start":1334,"enrollment":1405,"conditions":2073,"interventions":2077},"NCT00594087","Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)",[88],"2008-06",[2074,2075,2076],"Relapsing Remitting Multiple Sclerosis","Sleep Initiation and Maintenance Disorders","Fatigue",[2054],{"intervention":2079,"totalTrials":91,"cells":2080},"Ethinyl estradiol and norgestimate",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2082,"activeCount":95},[],{"trials":2084,"activeCount":95},[],{"trials":2086,"activeCount":95},[],{"trials":2088,"activeCount":95},[],{"trials":2090,"activeCount":95},[],{"trials":2092,"activeCount":95},[2093],{"nctId":2094,"briefTitle":2095,"status":363,"phases":2096,"completion":2097,"start":2098,"enrollment":367,"conditions":2099,"interventions":2101},"NCT00554632","Birth Control Pill vs Birth Control Patch Study",[88],"2005-08","2003-04",[2100],"Venous Thrombosis",[2079,2102],"Ethinyl estradiol and norelgestromin",{"intervention":2102,"totalTrials":91,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2106,"activeCount":95},[],{"trials":2108,"activeCount":95},[],{"trials":2110,"activeCount":95},[],{"trials":2112,"activeCount":95},[],{"trials":2114,"activeCount":95},[],{"trials":2116,"activeCount":95},[2117],{"nctId":2094,"briefTitle":2095,"status":363,"phases":2118,"completion":2097,"start":2098,"enrollment":367,"conditions":2119,"interventions":2120},[88],[2100],[2079,2102],{"intervention":2122,"totalTrials":91,"cells":2123},"Nicotine Replacement Therapy",{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2128,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2125,"activeCount":95},[],{"trials":2127,"activeCount":95},[],{"trials":2129,"activeCount":95},[],{"trials":2131,"activeCount":95},[],{"trials":2133,"activeCount":95},[],{"trials":2135,"activeCount":95},[2136],{"nctId":2137,"briefTitle":2138,"status":363,"phases":2139,"primaryCompletion":2140,"completion":2141,"start":2142,"enrollment":2143,"conditions":2144,"interventions":2145},"NCT05740098","Financial Incentives for Smoking Cessation Among Mothers",[88],"2019-12","2020-10","2015-06",198,[888],[2122],{"intervention":1856,"totalTrials":91,"cells":2147},{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2152,"PHASE3":2154,"PHASE4":2156,"NA":2158},{"trials":2149,"activeCount":95},[],{"trials":2151,"activeCount":95},[],{"trials":2153,"activeCount":95},[],{"trials":2155,"activeCount":95},[],{"trials":2157,"activeCount":95},[],{"trials":2159,"activeCount":95},[2160],{"nctId":1844,"briefTitle":1845,"status":363,"phases":2161,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2162,"interventions":2163},[88],[1851,1852,1853,1854],[1856,1857,1858,692],{"intervention":1857,"totalTrials":91,"cells":2165},{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2170,"PHASE3":2172,"PHASE4":2174,"NA":2176},{"trials":2167,"activeCount":95},[],{"trials":2169,"activeCount":95},[],{"trials":2171,"activeCount":95},[],{"trials":2173,"activeCount":95},[],{"trials":2175,"activeCount":95},[],{"trials":2177,"activeCount":95},[2178],{"nctId":1844,"briefTitle":1845,"status":363,"phases":2179,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2180,"interventions":2181},[88],[1851,1852,1853,1854],[1856,1857,1858,692],{"intervention":1858,"totalTrials":91,"cells":2183},{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2185,"activeCount":95},[],{"trials":2187,"activeCount":95},[],{"trials":2189,"activeCount":95},[],{"trials":2191,"activeCount":95},[],{"trials":2193,"activeCount":95},[],{"trials":2195,"activeCount":95},[2196],{"nctId":1844,"briefTitle":1845,"status":363,"phases":2197,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":2198,"interventions":2199},[88],[1851,1852,1853,1854],[1856,1857,1858,692],{"intervention":2201,"totalTrials":91,"cells":2202},"quetiapine",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2204,"activeCount":95},[],{"trials":2206,"activeCount":95},[],{"trials":2208,"activeCount":95},[],{"trials":2210,"activeCount":95},[],{"trials":2212,"activeCount":95},[],{"trials":2214,"activeCount":95},[2215],{"nctId":2216,"briefTitle":2217,"status":440,"phases":2218,"primaryCompletion":2219,"completion":1430,"start":2220,"enrollment":2221,"conditions":2222,"interventions":2225},"NCT00232570","Quetiapine for the Treatment of Insomnia in Alzheimer's Disease",[88],"2009-12","2005-11",18,[2223,2224],"Alzheimer's Disease","Insomnia",[2201],{"intervention":2227,"totalTrials":91,"cells":2228},"Budesonide",{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2230,"activeCount":95},[],{"trials":2232,"activeCount":95},[],{"trials":2234,"activeCount":95},[],{"trials":2236,"activeCount":95},[],{"trials":2238,"activeCount":95},[],{"trials":2240,"activeCount":95},[2241],{"nctId":2242,"briefTitle":2243,"status":363,"phases":2244,"primaryCompletion":1782,"completion":1782,"start":2245,"enrollment":209,"conditions":2246,"interventions":2249},"NCT02562924","The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery",[88],"2015-11",[2247,2248],"Chronic Sinusitis","Nasal Polyposis",[2227,2250,2251,2252],"Normal saline sinus rinse","Prednisone","nasal saline spray",{"intervention":2250,"totalTrials":91,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2256,"activeCount":95},[],{"trials":2258,"activeCount":95},[],{"trials":2260,"activeCount":95},[],{"trials":2262,"activeCount":95},[],{"trials":2264,"activeCount":95},[],{"trials":2266,"activeCount":95},[2267],{"nctId":2242,"briefTitle":2243,"status":363,"phases":2268,"primaryCompletion":1782,"completion":1782,"start":2245,"enrollment":209,"conditions":2269,"interventions":2270},[88],[2247,2248],[2227,2250,2251,2252],{"intervention":2251,"totalTrials":91,"cells":2272},{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2274,"activeCount":95},[],{"trials":2276,"activeCount":95},[],{"trials":2278,"activeCount":95},[],{"trials":2280,"activeCount":95},[],{"trials":2282,"activeCount":95},[],{"trials":2284,"activeCount":95},[2285],{"nctId":2242,"briefTitle":2243,"status":363,"phases":2286,"primaryCompletion":1782,"completion":1782,"start":2245,"enrollment":209,"conditions":2287,"interventions":2288},[88],[2247,2248],[2227,2250,2251,2252],{"intervention":2252,"totalTrials":91,"cells":2290},{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2301},{"trials":2292,"activeCount":95},[],{"trials":2294,"activeCount":95},[],{"trials":2296,"activeCount":95},[],{"trials":2298,"activeCount":95},[],{"trials":2300,"activeCount":95},[],{"trials":2302,"activeCount":95},[2303],{"nctId":2242,"briefTitle":2243,"status":363,"phases":2304,"primaryCompletion":1782,"completion":1782,"start":2245,"enrollment":209,"conditions":2305,"interventions":2306},[88],[2247,2248],[2227,2250,2251,2252]]